AGORACOM News Flash

AGORACOM WIRE - WEDNESDAY MAY 30TH, 2012

GOLDEN HOPE MINES (TSXV:GNH) Confirms High Grade Intersection of 64.1 g/t Au (Gold) over 1m Read More

The screen metallic analysis returned 82 g/t Au for an average grade of 93.5 g/t Au.
Two additional fire assays on the original pulp done prior to the screen metallic analyses returned 0.22 g/t Au and 0.12 g/t Au for an average fire assay grade of 0.41 g/t Au. The weighted average of all the fire assays and screen metallic assays from this 1-metre section in hole BD2011-184 is 64.1 g/t Au.

Sonomax® eers™ Custom Earbuds Announces Sponsorship of MUTEK 2012

Mutek provides an essential platform for 150 performers to showcase forward-thinking electronic music programming and new media to more than 25,000 attendees
Read Full Press Release; Read Why Sonomax?
Jump Into Active Discussion Forum
*Sponsor*

CONTINENTAL ENERGY Geothermal Energy Project Receives US$ 11.5 Million Grant Read More * Client

AGORACOM Launches Graphite Stocks Blog

NEWS - Haemacure Announces Webcast of Presentation at the Biotech/Pharma/Healt... Investor Forum

posted on May 12, 08 12:33PM

MONTREAL, QUEBEC, May 12, 2008 -- Haemacure Corporation (TSX:HAE), a Montreal based specialty bio-therapeutics company developing high-value human proteins for commercialization, announced today that its Chairman of the Board and Chief Executive Officer, Joseph Galli, will present at the upcoming Biotech/Pharma/Healthcare Investor Forum on Thursday, May 15th, 2008 at 12:30 Eastern Daylight Time.

The Investor Forum will webcast the audio portion of the presentation and post the associated slides via its website at www.investorcalendar.com/ClientPage.... hosted by PrecisionIR. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, simply cut and paste the abovementioned link or http://www.investorcalendar.com/ directly into your web browser.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

SOURCE: Haemacure Corporation

Haemacure Corporation

Joseph Galli Chairman and CEO

(514) 990-7074

Email: jgalli@haemacure.ca

Diane Roch Director, Communications

(514) 282-3350 ext. 27 or Cell.: (514) 952-3350

Email: droch@haemacure.ca

Website: www.haemacure.com